PMM2-CDG
Clinical trials for PMM2-CDG explained in plain language.
Never miss a new study
Get alerted when new PMM2-CDG trials appear
Sign up with your email to follow new studies for PMM2-CDG, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new treatment for rare PMM2-CDG disease enters final testing
Disease control OngoingThis study tests a new drug called GLM101 for people with PMM2-CDG, a rare inherited condition that causes problems with movement, balance, and coordination. About 50 children and adults will receive weekly infusions of either GLM101 or a placebo for 24 weeks, followed by 24 week…
Matched conditions: PMM2-CDG
Phase: PHASE2, PHASE3 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
Promising treatment for rare genetic disease continues testing
Disease control ENROLLING_BY_INVITATIONThis study offers continued access to the experimental drug GLM101 for people with PMM2-CDG, a rare genetic disorder that affects movement and development. Participants who completed a previous GLM101 trial will receive weekly infusions to see how safe the drug is over the long t…
Matched conditions: PMM2-CDG
Phase: PHASE2 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC